



August 2021

Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
USA

Dear Tecentriq Patient:

This letter is to inform you about an important change to Tecentriq[®] (atezolizumab).

Genentech, a member of the Roche Group, announced the decision to voluntarily withdraw Tecentriq for the treatment of Triple-Negative Breast Cancer (mTNBC) that is PD-L1 positive. This decision is not based on new safety or efficacy data, and does not affect other approved indications for Tecentriq.

If you are currently receiving Tecentriq for mTNBC that is PD-L1 positive, you should talk to your doctor about what the withdrawal means for you and your current treatment. You should discuss with your doctor the risks and the benefits of treatment with Tecentriq.

The withdrawal of the indication could mean that some insurers may no longer pay for Tecentriq for this type of cancer. If you are concerned about insurance coverage, please contact your insurance company's patient support line or Genentech for assistance. Genentech is committed to supporting patients who are currently benefiting from Tecentriq therapy and may be facing obstacles to receiving treatment. If your insurance has changed or you can't pay for your Genentech medicine, we may be able to help.

Please call the Genentech Patient Resource Center at 1-877-436-3683 and you will be connected to one of our patient support specialists who can help answer your questions.

We understand this may be a difficult time for you and your loved ones. Genentech's scientists, doctors and employees remain committed to advancing the scientific understanding of cancer and discovering new medicines.

This letter is not intended as a complete description of the benefits and risks related to the use of Tecentriq. Please refer to the Medication Guide for more information.

Sincerely,

Jamie Freedman MD, PhD
Head of U.S. Medical Affairs